AVI BioPharma Announces Presentations at 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Me
September 09 2010 - 12:00PM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, today announced upcoming presentations of preclinical
data evaluating AVI-7100 against pandemic influenza and AVI-6006
against dengue virus infection at the 50th Interscience Conference
on Antimicrobial Agents and Chemotherapy (ICAAC) taking place
September 12-15, 2010 in Boston, Massachusetts. Patrick Iversen,
Ph.D., Senior Vice President of Research and Innovation at AVI,
will make the following presentations:
Poster session 028(V), Influenza and Respiratory Viruses, on
Sunday, September 12. Dr. Iversen's presentation is titled "A Novel
Therapeutic Effective in a Ferret Model for Pandemic
Influenza."
Poster session 181(F1), New Antiviral Agents, on Tuesday,
September 14. Dr. Iversen's presentation is titled "New Therapeutic
for Dengue Infection: Efficacy Studies in a Mouse Model."
Both presentations will be posted on the AVI BioPharma website
in the "Our Programs" section after their respective poster
sessions are completed.
AVI-7100 and AVI-6006 are AVI's lead therapeutic candidates for
influenza and dengue virus infections, respectively. Both
candidates employ AVI's patented PMOplusā¢ technology that
selectively introduces positive charges to its phosphorodiamidate
morpholino oligomer (PMO) backbone to improve selective interaction
between the drug and its target.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
novel RNA-based therapeutics for rare and infectious diseases, as
well as other select disease targets. Applying pioneering
technologies developed and optimized by AVI, we are able to target
a broad range of diseases and disorders through distinct RNA-based
mechanisms of action. Unlike other RNA-based approaches, our
technologies can be used to directly target both messenger RNA
(mRNA) and precursor messenger RNA (pre-mRNA) to either
down-regulate (inhibit) or up-regulate (promote) the expression of
targeted genes or proteins. By leveraging our highly differentiated
RNA antisense-based technology platform, we have built a pipeline
of potentially transformative therapeutic agents, including a
clinical stage Duchenne muscular dystrophy candidate and
anti-infective candidates for influenza and hemorrhagic fever
viruses. For more information, visit www.avibio.com.
Forward-Looking Statements and Information
This press release contains statements that are forward-looking,
including statements about AVI's technologies and their efficacy,
potency and utility in the treatment of infectious diseases, and
their potential to treat a broad number of human diseases. These
forward-looking statements involve risks and uncertainties, many of
which are beyond AVI's control, including that preclinical and
clinical trials may not demonstrate safety and efficacy of any of
our drug candidates and/or our antisense-based technology platform,
and any of our drug candidates may fail in development, may not
receive required regulatory approvals, or be delayed to a point
where they do not become commercially viable.
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024